Prelude Therapeutics Inc Ordinary Shares PRLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
-
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
-
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Prelude Therapeutics Gains on FDA Greenlight for Phase 1 Blood-Cancer Drug Trial
Trading Information
- Previous Close Price
- $3.23
- Day Range
- $3.20–3.44
- 52-Week Range
- $1.16–6.83
- Bid/Ask
- $3.10 / $3.44
- Shares Outstanding
- 79.80M
- Market Cap
- $264.95M
- Volume/Avg
- 400,250 / 477,261
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 79
- Website
- https://www.preludetx.com
Valuation
|
Metric
|
PRLD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.12 |
Price/Sales | 13.37 |
Price/Cash Flow | — |
Price/Earnings
PRLD
Financial Strength
|
Metric
|
PRLD
|
|---|---|
Quick Ratio | 3.99 |
Current Ratio | 4.07 |
Interest Coverage | — |
Quick Ratio
PRLD
Profitability
|
Metric
|
PRLD
|
|---|---|
Return on Assets (Normalized) | −39.54% |
Return on Equity (Normalized) | −65.75% |
Return on Invested Capital (Normalized) | −53.71% |
Return on Assets
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|f^@wwxX | LOCK|?k^w# | $126B | |||
| Moderna Inc
MRNA
| LOCK|JzgkXQ | LOCK|w@R | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!l!#b? | LOCK|bK#?< | $80B | |||
| argenx SE ADR
ARGX
| LOCK|HfY&&? | LOCK|&W | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FdB#c# | LOCK|Q$! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|??xttr | LOCK|$y%# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|v?^&?>V | LOCK|g^%$x | $26B | |||
| Incyte Corp
INCY
| LOCK|q@B@%<@ | LOCK|^@c | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|g%$RZb | LOCK|y>< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|xCS%$&D | LOCK|!# | $14B |
United States